Toggle navigation
TWunroll
TWunroll
faq
Contact US
Shrey Srivastava
BlogShrey
#DDDD $DDDD $LBPS $LOACMRx0518 seems to be the gift that keeps on giving right now!The 'clinical trial collaboration and supply agreement with Merck KGaA, Darmstadt, Germany and Pfizer' is fantastic
Read more
#DDDD $DDDD $LBPS $LOACA very promising RNS today.Bit by bit analysis below. #DDDD $DDDD $LBPS $LOAC'We have generated additional safety and efficacy data, building on the positive data from both
Read more
#DDDD $DDDD $LBPS $LOACWhy exactly will 4d Pharma benefit from a NASDAQ listing?What makes NASDAQ the catalyst, in my opinion which will drive a 4d Pharma re-rate?An explanation: #DDDD $DDDD
Read more
#DDDD $DDDD $LBPS $LOAChttp://thepharmaletter.com/article/platforms-versus-products-in-the-life-sciences-sector'One common such weakness is often the failure of management teams to differentiate between the value of technology-derived m
Read more
My take on recent sentiment on the American right: Republicans used to prioritise community. Reagan Republicans used to keep 'family values' central to their policy.Nowadays you can boil many of
Read more
#DDDD $DDDD $LBPS $LOAChttps://www.genengnews.com/news/merck-co-launches-up-to-2-5b-cancer-collaboration-with-taiho-astex/More Merck $MRK news that bodes very well for 4d Pharma, specifically in (immuno-)oncology. 'Merck & Co. said
Read more
#SAEI thought I'd make a thread on my newest core holding, Simec Atlantis Energy.After selling Eqtec #EQT, I felt the need to keep a significant % of my portfolio in
Read more
#DDDD $LBPS $LOACA thread on the potential near term catalysts behind why I have increased my position in 4d Pharma @4dpharmaplc (LON: #DDDD): 1) NASDAQ listing. This is the most
Read more
The more I read about 4d Pharma #DDDD, the more I am convinced that they must be being looked at as a potential buyout target. A buyer would get:- 10+
Read more
Last #DDDD research for a while.Based on research from https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6609997/#:~:text=Failures%20in%20phase%20II%20testing,(15%25)%20(10) and https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6092479/#:~:text=respe
Read more
While looking at speculative pharmaceutical stocks I am reminded of why I am averse to these risky picks.#DDDD was compelling enough, though, to break this rule. The 10+ treatments under
Read more
I realised my tweets about #SEE have been quite fragmented, so I thought I'd do a thread summarising the stunning investment case (and why I think it will see further
Read more
‹
1
2
›
By continuing to use the site, you are consenting to the use of cookies as explained in our
Cookie Policy
to improve your experience.
I agree